指南与共识骨质疏松与钙磷/甲状旁腺

成人X连锁低磷血症管理:国际工作组临床实践指南

X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2025-01-01

国际工作组(IWG)基于两项系统综述与叙述性综述制定成人X连锁低磷血症(XLH)全球指南,采用GRADE方法评价证据确定性。指南建议有骨折或假骨折的成人XLH患者使用布罗索尤单抗而非无治疗(强推荐,GRADE分级),无骨折或假骨折时建议布罗索尤单抗优于传统治疗(条件推荐,GRADE分级);若布罗索尤单抗不可及,有症状成人应接受传统治疗(非GRADE推荐)。

要点

  • 有骨折或假骨折的成人XLH患者,推荐布罗索尤单抗而非无治疗(强推荐,GRADE分级)。
  • 无骨折或假骨折时,建议布罗索尤单抗优于传统治疗(条件推荐,GRADE分级)。
  • 若布罗索尤单抗不可及,有症状成人应接受传统治疗(非GRADE推荐)。

核心结论

  • 成人XLH合并骨折或假骨折时,推荐布罗索尤单抗而非无治疗(强推荐,GRADE分级)。
  • 无骨折或假骨折时,建议布罗索尤单抗作为首选治疗优于传统治疗(条件推荐,GRADE分级)。
  • 若布罗索尤单抗不可及,有症状成人应接受传统治疗(非GRADE推荐)。

研究设计与样本

  • 国际工作组(IWG)由43名成员及方法学家和一名患者伙伴组成,开展2项系统综述和叙述性综述。
  • 系统综述评估布罗索尤单抗对比传统治疗(磷酸盐和活性维生素D)或无治疗对成人患者重要结局的影响,并评估传统治疗对比无治疗。
  • 采用GRADE方法评价证据确定性;证据不足以开展系统综述时作出非GRADE推荐。
  • 指南已获多个医学和患者学会及组织审阅和认可。

主要发现

  • XLH诊断基于整合临床评估、证实肾磷酸盐丢失的实验室检查(排除模拟XLH的疾病后)及骨骼影像学。
  • 成纤维细胞生长因子23测定和DNA分析在诊断中有价值(如可及)。
  • PHEX基因致病或可能致病变异可确诊,但非诊断所必需。
  • 管理需要熟悉XLH的多学科团队。
  • 布罗索尤单抗有效药物治疗可改善骨折和假骨折愈合。

关键数值与推荐

  • 有骨折或假骨折的成人XLH患者:布罗索尤单抗 vs 无治疗(强推荐,GRADE分级)。
  • 无骨折或假骨折的成人XLH患者:布罗索尤单抗 vs 传统治疗(条件推荐,GRADE分级)。
  • 布罗索尤单抗不可及时:有症状成人接受传统治疗(非GRADE推荐)。

临床怎么用

  • 有骨折或假骨折的成人XLH患者推荐使用布罗索尤单抗而非无治疗(强推荐,GRADE分级)。
  • 无骨折或假骨折时建议布罗索尤单抗作为首选治疗优于传统治疗(条件推荐,GRADE分级)。
  • 布罗索尤单抗不可及时,有症状成人应接受传统治疗(非GRADE推荐)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: An international working group (IWG) consisting of experts in X-linked hypophosphatemia (XLH) developed global guidelines providing a comprehensive, evidence-based approach to XLH diagnosis, management, and monitoring. METHODS: The IWG, consisting of 43 members as well as methodologists and a patient partner, conducted 2 systematic reviews (SRs) and narrative reviews to address key areas. The SRs addressed the impact of burosumab compared to conventional therapy (phosphate and active vitamin D) or no therapy on patient-important outcomes in adults. They also evaluated conventional therapy compared to no therapy. GRADE methodology was applied to evaluate the certainty of evidence. Non-GRADED recommendations were made in the presence of insufficient evidence to conduct SRs. These guidelines have been reviewed and endorsed by several medical and patient societies and organizations. RESULTS: The diagnosis of XLH is based on integrating clinical evaluation, laboratory findings confirming renal phosphate wasting (following exclusion of conditions mimicking XLH), and skeletal imaging. Fibroblast growth factor 23 measurement and DNA analysis are of value in the diagnosis, if available. Pathogenic or likely pathogenic variants in the PHEX gene are confirmatory but not necessary for the diagnosis. Management requires a multidisciplinary team knowledgeable and experienced in XLH. Effective medical therapy with burosumab can improve fracture and pseudofracture healing. MAIN CONCLUSION: In adults with XLH and fractures or pseudofractures, burosumab is recommended over no therapy (strong recommendation, GRADEd). Additionally, burosumab is suggested as the preferred treatment compared to conventional therapy (conditional recommendation, GRADEd) in the absence of fractures or pseudofractures. If burosumab is not available, symptomatic adults should be treated with conventional therapy (Non-GRADEd recommendation).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Khan AA, Ali DS, Appelman-Dijkstra NM, et al. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025. PMID: 40243526. doi:10.1210/clinem/dgaf170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。